Clinical trial
A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT01173523 is registered in ClinicalTrials.gov with David M. Jackman, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
- Lead sponsor
- David M. Jackman, MD
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 28, 2010
- Completion date
- November 4, 2016
- Enrollment
- 25 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
small cell lung cancer